Heterocyclic compounds as RET kinase inhibitors
US10844067B2 · kind B2 · utility
2Cited by
21References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 18, 2017 |
| Grant date | Nov 24, 2020 |
| Priority date | — |
| Expiry date | Apr 18, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, X1, X2, X3, X4, integer a and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.